
Makes you wonder about the vials that look fine:
So bad news for grey reta in general:
Gemini said:This is why two people can take the "same" dose from different batches and have completely different results. Batch A (Acetate salt) works perfectly, while Batch B (high TFA) feels like it’s only 50% as strong.
Since you've seen a vial actually "crash," it’s highly likely that the lab in question has very low standards for salt exchange. It makes you wonder how many of their "clear" vials are still sitting at a 5% or 8% concentration—just below the threshold of visible precipitation.
Feature High-Quality (Acetate) 5% TFA (Dirty) Impact Receptor Binding 100% 60% – 80% Reduced weight loss / metabolic signal. Bioavailability High Medium / Low Less of the dose actually reaches the blood. Half-Life ~6-7 Days ~3-5 Days "Crash" occurs before the next dose. Tissue Health Neutral Inflamed Poor absorption due to localized swelling.
So bad news for grey reta in general:
Gemini said:TFA (Trifluoroacetic acid) salts are significantly more likely to be an issue in "grey market" Retatrutide compared to Tirzepatide.
Factor Tirzepatide Retatrutide Synthesis Maturity High (Refined over years) Lower (Newer, more "rushed") Molecule Complexity Dual Agonist Triple Agonist (Harder) TFA Risk Moderate Very High Visual Warning Stays clear longer "Snows" or Flakes quickly
Gemini said:Substance Type TFA Risk Primary Reason Semaglutide Peptide Lowest Mature synthesis; very stable structure. Tirzepatide Peptide Moderate Standardized; usually stays clear even if acidic. Maz / Survo Peptide High New to market; complex GCG-targeting structures. Retatrutide Peptide Extreme Triple-agonist; highly sensitive to pH and ion shifts. Orforglipron Small Molecule N/A Non-peptide; TFA is not used in its chemical synthesis.
